The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo； materials and methods for editing a USH2A gene in a human cell； materials and methods for editing an USH2A gene containing an IVS40 mutation； materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation； and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A.
